In this post in Huffington Post’s “Impact” blog, Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, examines “the success of U.S. efforts to promote better global health through support for [PEPFAR] and the Global Fund to Fight AIDS, Tuberculosis and Malaria.” She highlights U.S. Secretary of State Hillary Clinton’s recent trip to Africa, writing that Clinton’s “encouraging words” at the Reach Out Mbuya health center in Uganda reinforced U.S. commitment to an AIDS-free generation. She notes both PEPFAR and the Global Fund have supported the center and adds that “through hundreds of similar local programs all over the world, the Global Fund provides treatment to 3.6 million people who are HIV-positive.”
“PrePex, a bloodless circumcision device for adults, will be tested in at least nine African countries in the next year, according to the backers of the tests,” the New York Times reports. PEPFAR “will pay for PrePex circumcisions for about 2,500 men in Lesotho, Malawi, South Africa, Tanzania and Uganda, said Dr. Jason B. Reed, a technical adviser to the plan,” the newspaper writes. “The Bill & Melinda Gates Foundation will pay for similar studies in Kenya, Mozambique, South Africa, Zambia and Zimbabwe,” it adds. According to the New York Times, the device “was approved by the Food and Drug Administration in January, and World Health Organization approval is expected soon.” The newspaper notes, “No surgeon is needed for the procedure; a two-nurse team slides a grooved ring inside the foreskin and guides a rubber band to compress the foreskin in the groove,” and adds, “After a week, the dead foreskin falls off like the stump of a baby’s umbilical cord or can be painlessly clipped off, said Tzameret Fuerst, chief executive of PrePex” (McNeil, 8/13).
“With Congress adjourned until after Labor Day and not a single funding bill for the federal fiscal year beginning October signed into law before the recess even began, the virtual standstill of legislative action could have a mixed impact on global health funding,” the Center for Global Health Policy’s “Science Speaks” blog reports. “It appears that House and Senate leaders have reached a tentative agreement to fund most government programs under a so-called ‘continuing resolution’ that would essentially continue funding for most programs at current levels through March 30, 2013,” the blog writes, adding, “PEPFAR is likely to see at least a modest cut from current funding so that resolution could delay or potentially reduce the overall hit to the program” (Lubinski , 8/10).
In this post in Global Post’s “Global Pulse” blog, Mitchell Warren, executive director of AVAC, and Chris Collins, vice president and director of public policy at amfAR, write that “the world needs a business plan to end AIDS.” They continue, “To us, ending the epidemic means drastically reducing new HIV infections, while preserving the health of everyone living with HIV,” adding, “This is an ambitious vision, and it is achievable if we make smart use of the HIV prevention and treatment options available today, while continuing the search for a vaccine and a cure. It will require clear priorities, ambitious and achievable targets, sustained funding and effective ways to hold ourselves accountable for progress.”
In this post in the Center for Global Development’s (CGD) “Global Health Policy” blog, Amanda Glassman, director of global health policy and a research fellow at the center, and Denizhan Duran, a research assistant at the center, examine several recent studies evaluating the use of cash transfers as a strategy against HIV/AIDS. They state that “a new generation of cash transfer programs in sub-Saharan Africa is reducing new infections and HIV-related risky behavior — and documenting the gains — while also providing consumption, nutrition, education, and mental health benefits to the orphans and vulnerable children who are the primary targets of some programs.” Glassman and Duran conclude, “With the new batch of evaluation results on cash transfers, there may be more reasons to invest in these kinds of programs, particularly the at-scale national programs targeted to the poor” (8/8).
The Center for Global Health Policy’s “Science Speaks” blog examines how the “U.S. travel bans on people involved in sex work and people who have used illegal drugs … kept many of the people at highest risk from coming to the [XIX International AIDS Conference (AIDS 2012)]” in Washington, D.C., last month. “The result, observers said afterward, was a larger conference with fewer sex workers than had brought their first-hand experiences and concerns to Vienna and Mexico City,” according to the blog. Carlos Laudari, senior technical adviser for HIV AIDS prevention at Pathfinder, “and others said those in absentia were not the only ones disempowered; the loss of sex worker and drug user input on how to realize the goals of treatment as prevention, on barriers to funding, testing, health care access, and for that matter, on the difference between sex work and sex trafficking — commonly, and erroneously equated — weakened the dialogue and the action they were intended to inform,” the blog writes and quotes several other advocates (Barton, 8/8).
“Methadone treatment is proving to be the most efficient way to wean people in Bangladesh from addiction to buprenorphine, a pharmaceutical drug, and health experts say it should be expanded to reach thousands more drug users to prevent the spread of HIV,” IRIN reports. The news service notes that “illegal use of pharmaceutical substances, mostly buprenorphine, is on the rise” in the country. “Buprenorphine was intended to be used to wean injecting drug users, also known as people who inject drugs (PWID), from narcotics like heroin, but has itself become a substance of addiction, with users injecting a liquid form of it,” the news service notes, adding, “Methadone, a pain reliever, suppresses withdrawal symptoms and blocks craving.”
Advocacy Groups Warn Trans-Pacific Partnership Could Affect Access To Low-Cost Medications, Bloomberg Reports
Bloomberg Businessweek examines how ongoing trade negotiations related to the Trans-Pacific Partnership could affect access to quality low-cost medications, including antiretrovirals, in low- and middle-income countries. “Protecting the patents of drug makers … as part of the Trans-Pacific Partnership has drawn criticism from groups such as Doctors Without Borders and Public Citizen,” and “[t]he proposed accord has also spurred calls from U.S. lawmakers for greater transparency about the negotiations,” the news service writes. “The multilateral talks, the main accord being pursued by President Barack Obama’s administration, … began with Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the U.S. and Vietnam [and] may expand after the parties invited Canada and Mexico,” the news service notes.
The Centers for Disease Control and Prevention (CDC) has developed a new HIV test, called the Limiting Antigen Avidity Enzyme Immunoassay, that can tell whether a person contracted the virus within the last 141 days, “hugely important information for researchers, who need to know whether fewer people are becoming newly infected with HIV to determine whether a prevention program is working,” the Wall Street Journal’s “Health Blog” reports. Speaking last month at the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., “Secretary of Health and Human Services Kathleen Sebelius called the new test ‘a major development that will help us better evaluate and improve our prevention efforts,'” the blog notes.
“U.S. Secretary of State Hillary Clinton said during a visit to South Africa that Pretoria will begin taking more of the responsibilities for its HIV/AIDS program, part of a broader effort to overhaul the U.S. global plan for AIDS relief launched under former President George W. Bush,” Reuters reports. “On Wednesday, Clinton is expected to sign a deal to rework South Africa’s programs under [PEPFAR], allowing the government to better use the funding in its fight against the virus,” the news service writes.